Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2028

Conditions
Craniopharyngioma, ChildCraniopharyngiomaRecurrent Craniopharyngioma
Interventions
DRUG

Tovorafenib

Given orally

Trial Locations (14)

10016

RECRUITING

NYU Langone Health, New York

19103

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

21218

RECRUITING

John Hopkins University, Baltimore

27710

RECRUITING

Duke University Medical Center, Durham

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

46202

RECRUITING

Riley Hospital for Children at Indiana University Health, Indianapolis

48109

RECRUITING

University of Michigan, Ann Arbor

55404

RECRUITING

Children's Minnesota, Minneapolis

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

RECRUITING

St. Louis Children's Hospital Washington University, St Louis

84112

RECRUITING

University of Utah, Salt Lake City

92037

RECRUITING

Rady Children's Hospital/University of California, San Diego, San Diego

94143

RECRUITING

University of California, San Francisco, San Francisco

02215

RECRUITING

Dana-Farber/Boston Children's Harvard Medical School, Boston

Sponsors
All Listed Sponsors
collaborator

Day One Biopharmaceuticals, Inc.

INDUSTRY

lead

Sabine Mueller, MD, PhD

OTHER

NCT05465174 - Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Biotech Hunter | Biotech Hunter